Warner Chilcott announced that the FDA has approved Lo Loestrin FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets, and ferrous fumarate tablets) for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Lo Loestrin FE is a low dosage oral contraceptive that contains 24 tablets containing 1mg norethindrone acetate and 10mcg ethinyl estradiol, two tablets containing 10mcg ethinyl estradiol, and two tablets containing 75mg of ferrous fumarate.

Lo Loestrin FE is expected to be available in early 2011.

For more information call (800) 521-8813 or visit www.wcrx.com.